From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy (Q36352100)

13 August 2017

1 reference

title

From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy (English)

1 reference

13 August 2017

1 reference

Georgios V Georgakis

1

1 reference

13 August 2017

Anas Younes

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

131-140

1 reference

Mammalian target of rapamycin

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phosphorylation and activation of p70s6k by PDK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Structure, regulation and function of PKB/AKT--a major therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

The human gene encoding FKBP-rapamycin associated protein (FRAP) maps to chromosomal band 1p36.2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Regulation of cellular growth by the Drosophila target of rapamycin dTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Tuberous sclerosis: from tubers to mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

De novo germline mutation in the serine-threonine kinase STK11/LKB1 gene associated with Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

LKB1 is the upstream kinase in the AMP-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Integrin-linked kinase: a cancer therapeutic target unique among its ILK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Will mTOR inhibitors make it as cancer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

The Akt kinase signals directly to endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phosphorylation and regulation of Raf by Akt (protein kinase B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

CREB is a regulatory target for the protein kinase Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt phosphorylates and regulates the orphan nuclear receptor Nur77

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Modulation of p47 PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

Phosphorylation and Activation of Heart 6-Phosphofructo-2-kinase by Protein Kinase B and Other Protein Kinases of the Insulin Signaling Cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.1.131

21 January 2018

Identifiers

DOI

10.1586/14737140.6.1.131

1 reference

13 August 2017

1 reference